Ninety One UK Ltd Sells 218,812 Shares of Natera, Inc. $NTRA

by · The Cerbat Gem

Ninety One UK Ltd trimmed its stake in Natera, Inc. (NASDAQ:NTRA – Free Report) by 38.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 344,173 shares of the medical research company’s stock after selling 218,812 shares during the quarter. Ninety One UK Ltd owned 0.25% of Natera worth $55,402,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its position in Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 106 shares during the period. Hilltop National Bank purchased a new stake in Natera during the 2nd quarter valued at $33,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Natera during the 2nd quarter valued at $36,000. AlphaQuest LLC boosted its stake in shares of Natera by 1,857.1% in the 1st quarter. AlphaQuest LLC now owns 274 shares of the medical research company’s stock worth $39,000 after buying an additional 260 shares during the last quarter. Finally, Sound Income Strategies LLC grew its holdings in shares of Natera by 95.7% in the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after acquiring an additional 110 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $229.09 on Thursday. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $246.90. The company has a market capitalization of $31.69 billion, a P/E ratio of -100.04 and a beta of 1.63. The firm’s 50 day simple moving average is $220.68 and its two-hundred day simple moving average is $182.83.

Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same period last year, the company earned ($0.26) earnings per share. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 4,400 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $238.07, for a total transaction of $1,047,508.00. Following the completion of the sale, the chief executive officer owned 140,416 shares in the company, valued at approximately $33,428,837.12. This trade represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 4,692 shares of Natera stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $230.76, for a total value of $1,082,725.92. Following the sale, the insider directly owned 113,065 shares in the company, valued at $26,090,879.40. This trade represents a 3.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 336,481 shares of company stock worth $72,008,879 in the last three months. 5.63% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent research reports. Stephens increased their target price on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Wells Fargo & Company increased their price objective on shares of Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Morgan Stanley raised their price objective on shares of Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. Canaccord Genuity Group upped their target price on shares of Natera from $250.00 to $285.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, UBS Group increased their price target on shares of Natera from $218.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Fifteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $231.18.

Check Out Our Latest Analysis on Natera

About Natera

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Further Reading

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).